Painful cervical esophageal erosion in a patient with advanced colorectal cancer treated with bevacizumab

Author： Paiva Carlos   Maia Yara   Paiva Bianca   Lerco Mauro  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.28, Iss.6, 2010-12, pp. : 882-883

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab in colorectal cancer: profile report

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 21, Iss. 5, 2005-05 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite

Bevacizumab an improvement on standard therapy in colorectal cancer

By  

Inpharma, Vol. 1, Iss. 1399, 2003-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Bevacizumab: A Review of its Use in Metastatic Colorectal Cancer

By McCormack Paul L.   Keam Susan J.  

Drugs, Vol. 68, Iss. 4, 2008-01 ,pp. : 487-506

Adis International

Access to resources Recommend Favorite

Vascular biology support for the use of bevacizumab in colorectal cancer

By Doggrell Sheila A  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 6, 2004-06 ,pp. : 703-705

Informa Healthcare

Access to resources Recommend Favorite

Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer

By Madajewicz Stefan  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 772-778

Springer Publishing Company

Access to resources Recommend Favorite